Spike Protein News and Research

RSS

Identifying SARS-CoV-2 spike protein mutations resistant to antibodies

Using a set of different monoclonal antibodies, researchers determined different mutations in the SARS-CoV-2 spike protein that leads to resistance. Understanding these resistant mutations is important in developing effective therapeutic strategies.

10 Nov 2020

Exosome-mediated mRNA delivery generates broad immune response to multiple SARS-CoV-2 proteins

Recently, researchers from The Johns Hopkins University School of Medicine, Baltimore, MD, USA, and Capricor Therapeutics, Inc., Beverly Hills, CA, USA, described a new approach to SARS-CoV-2 vaccine development using exosomes to deliver mRNAs that encode the antigens from multiple structural proteins of the virus.

9 Nov 2020

Promising yeast-expressed SARS-CoV-2 vaccine candidate effective in mice

Researchers at the Texas Children's Hospital Center for Vaccine Development, USA, have published a report on the preprint server bioRxiv that describes a yeast-expressed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) protein, a key target of current vaccine development efforts.

9 Nov 2020

ACE2 and TMPRSS2 not the only virus-receptors to mediate SARS-CoV-2 entry

However, a recent study published on the preprint server bioRxiv in November 2020 uncovers the major role played by the N-terminal domain of the SARS-CoV-2 virus in host infection. This could be of great use in measuring the usefulness of antibodies used in convalescent plasma therapy for COVID-19.

9 Nov 2020

Immune-evading variants can emerge in SARS-CoV-2, researchers warn

An international team of researchers has shown that a mutation within severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) – enables the pathogen to evade antibody-mediated immunity while maintaining replication fitness and increasing viral loads.

9 Nov 2020

Pre-existing antibodies created during COVID-19 may protect children against new pandemic strain

Researchers at the Francis Crick Institute and University College London have found that some antibodies, created by the immune system during infection with common cold coronaviruses, can also target SARS-CoV-2 and may confer a degree of protection against the new viral strain.

9 Nov 2020

Study shows SARS-CoV-2 direct heart muscle cell infection, cell death, loss of contractility

In the study, published on the pre-print journal bioRxiv, the researchers revealed that SARS-CoV-2-infected EHTs manifested the typical characteristics of myocarditis or heart inflammation. These include the stimulation of immune cells, heart cell death, and decreased contractile force generation.

8 Nov 2020

SARS-CoV-2 viral antigens found in non-pulmonary tissues in recovering patients

A team of researchers in Singapore, led by Dr. Joe Yeong, and Prof. Tony Kiat Hon Lim, have reported the presence of residual SARS-CoV-2 ribonucleic acid (RNA) – the virus' genetic material – in stool samples and gastrointestinal tissues from patients recovering from the coronavirus disease 2019 (COVID-19).

8 Nov 2020

Study shows SARS-CoV-2 infection four times more likely through household transmission than community

A group of researchers from across the United States working in collaboration with their Swiss counterparts have conducted an extensive population-based serological survey to understand the transmission dynamics of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) – the novel agent that causes coronavirus disease 2019 (COVID-19).

8 Nov 2020

Universal nanoparticle platform may help in rapid development of a COVID-19 vaccine

A research group in China recently published a paper on the pre-print server bioRxiv* that reports the performance of a potentially universal nanoparticle platform that may prove useful for the rapid development of a COVID-19 vaccine, as well as other vaccines in the future.

8 Nov 2020

Research describes novel molecules designed to treat or prevent COVID-19 infection

Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.

6 Nov 2020

Persistent and extensive lung damage seen in COVID-19 patients

A team of researchers at the University of Trieste in Italy aimed to determine the extent and the causes of lung damage from COVID-19 to better understand the pathological correlates of the disease.

5 Nov 2020

Llama antibodies could be a potent nanoweapon against COVID-19

Today in Science, researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat COVID-19.

5 Nov 2020

Children produce different antibodies in response to infection with new coronavirus

Children and adults produce different types and amounts of antibodies in response to infection with the new coronavirus, SARS-CoV-2, a new study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found.

5 Nov 2020

Nanobodies efficiently neutralize SARS-CoV-2 in cells

Two separate studies have identified nanobodies - which could be produced less expensively than monoclonal antibodies - that bind tightly to the SARS-CoV-2 spike protein and efficiently neutralize SARS-CoV-2 in cells.

5 Nov 2020

Argonne supports the largest analysis of COVID-19 genome sequences in the U.S.

Argonne computational resources supported the largest comprehensive analysis of COVID-19 genome sequences in the U.S. and helped corroborate growing evidence of a protein mutation.

5 Nov 2020

Researchers identify antibodies that prevent SARS-CoV-2 from infecting human cells

The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2.

5 Nov 2020

Zinc-embedded polyamide fabrics are effective in absorbing and inactivating SARS-CoV-2

An international team of scientists has recently demonstrated that zinc-embedded polyamine fibers can effectively absorb and inactivate human respiratory viruses, including influenza A virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Thus, a face mask or other personal protective equipment (PPE) made from this fiber is expected to provide better protection against viral transmission.

4 Nov 2020

Computational study reveals SARS-CoV-2 spike protein structural stability

Using dynamic contact maps and energy differences between different conformations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (or S-protein), an international team of researchers have recently published an article on the bioRxiv preprint server showing the different stable conformations of the spike protein.

4 Nov 2020

An analysis of genetic diversity of D614G mutation in SARS-CoV-2

A new study published in the preprint server bioRxiv in November 2020 reports that the effect of the mutation is minimal, in terms of pathogenicity or altered response to neutralizing antibodies elicited against the native virus strain.

4 Nov 2020

Spike Protein News and Research

Identifying SARS-CoV-2 spike protein mutations resistant to antibodies

Exosome-mediated mRNA delivery generates broad immune response to multiple SARS-CoV-2 proteins

Promising yeast-expressed SARS-CoV-2 vaccine candidate effective in mice

ACE2 and TMPRSS2 not the only virus-receptors to mediate SARS-CoV-2 entry

Immune-evading variants can emerge in SARS-CoV-2, researchers warn

Pre-existing antibodies created during COVID-19 may protect children against new pandemic strain

Study shows SARS-CoV-2 direct heart muscle cell infection, cell death, loss of contractility

SARS-CoV-2 viral antigens found in non-pulmonary tissues in recovering patients

Study shows SARS-CoV-2 infection four times more likely through household transmission than community

Universal nanoparticle platform may help in rapid development of a COVID-19 vaccine

Research describes novel molecules designed to treat or prevent COVID-19 infection

Persistent and extensive lung damage seen in COVID-19 patients

Llama antibodies could be a potent nanoweapon against COVID-19

Children produce different antibodies in response to infection with new coronavirus

Nanobodies efficiently neutralize SARS-CoV-2 in cells

Argonne supports the largest analysis of COVID-19 genome sequences in the U.S.

Researchers identify antibodies that prevent SARS-CoV-2 from infecting human cells

Zinc-embedded polyamide fabrics are effective in absorbing and inactivating SARS-CoV-2

Computational study reveals SARS-CoV-2 spike protein structural stability

An analysis of genetic diversity of D614G mutation in SARS-CoV-2

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News